CN115671178A - Composition comprising beta-nicotinamide mononucleotide and rosa roxburghii tratt extract and application thereof - Google Patents
Composition comprising beta-nicotinamide mononucleotide and rosa roxburghii tratt extract and application thereof Download PDFInfo
- Publication number
- CN115671178A CN115671178A CN202110831357.4A CN202110831357A CN115671178A CN 115671178 A CN115671178 A CN 115671178A CN 202110831357 A CN202110831357 A CN 202110831357A CN 115671178 A CN115671178 A CN 115671178A
- Authority
- CN
- China
- Prior art keywords
- composition
- nicotinamide mononucleotide
- extract
- beta
- rosa roxburghii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Abstract
The invention relates to a composition containing beta-nicotinamide mononucleotide and a roxburgh rose extract and application thereof, belonging to the technical field of biological medicines. The invention provides a composition containing beta-Nicotinamide Mononucleotide (NMN) and a roxburgh rose extract and application thereof. The active ingredients of the composition consist of the following components in percentage by weight: 45-65% of beta-nicotinamide mononucleotide, and the balance of roxburgh rose extract. According to the invention, through compounding of NMN and the roxburgh rose extract, intestinal flora disorder is effectively improved and aging is delayed under the condition of reducing the dosage of NMN.
Description
Technical Field
The invention relates to a composition containing beta-nicotinamide mononucleotide and a roxburgh rose extract and application thereof, belonging to the technical field of biological medicines.
Background
A large number of microbial floras exist in intestinal tracts of a human body, interact with each other to form a complex and relatively stable microecosystem, participate in a plurality of processes such as human body immunoregulation, biological antagonism, tumor inhibition, lipid metabolism, nutrient absorption and the like, and have very important effects on human health. The microbial flora in human intestinal tract can be more than 1000, and the number of the microbial flora is ten times of the number of human cells. The intestinal flora is normally kept in a relatively balanced state, and under the stimulation of some factors, the intestinal flora is disordered, so that various diseases such as obesity, senile dementia, tumor, depression and the like are caused. Many factors causing dysbacteriosis include long-term and large-scale use of antibiotics, constipation, diet, living habits, environmental factors and mental factors.
Currently, the main approach to improving the intestinal flora is to supplement probiotics. However, the live bacteria used by the method reach the intestinal tract through the extreme environment such as gastric acid, bile and the like after being produced, sold on a shelf and eaten, and the test at this stage consumes the activity of the probiotics, so that the production and storage cost of the probiotics is greatly increased.
Beta-nicotinamide mononucleotide (abbreviated as NMN) is a naturally occurring bioactive nucleotide, has important physiological functions for human cells, can be naturally synthesized in the cells, and can also be derived from various foods such as broccoli, cabbage, cucumber, green soybean and the like. Chinese patent CN111557949A discloses a composition of hydrogen-rich water and NMN, and the results of the patent show that the NMN has certain effect of improving intestinal flora when being continuously administered to HFA mice by intragastric administration for 30 days under the dosage of 22 g/kg/day. It can be seen that if the NMN is used alone to improve the intestinal flora, the dosage is too large, which results in high cost and influences the popularization and application.
Roxburgh rose is a natural plant used as both medicine and food, and is collected in Ben Cao gang mu and Chinese medicine dictionary. The Rosa roxburghii fruit is rich in nutrient elements such as flavone, polysaccharide, vitamins, superoxide dismutase (SOD) and organic acid, and has the functions of regulating organism immunity, delaying aging, resisting atherosclerosis and tumor, etc. Studies show that the rosa roxburghii tratt polysaccharide can improve the abundance of beneficial bacteria and reduce the abundance of harmful bacteria in the intestinal tract of diabetic db/db mice to a certain extent, but has no significant influence on the diversity index and abundance of intestinal microorganisms (Wang et al, journal of Functional Foods,2019, 52.
Disclosure of Invention
In view of the above defects, the technical problem to be solved by the present invention is to provide a composition for improving intestinal flora and enhancing anti-aging ability by combining beta-nicotinamide mononucleotide and rosa roxburghii tratt extract.
The invention relates to a composition containing beta-nicotinamide mononucleotide and a roxburgh rose fruit extract, which comprises the following active ingredients in percentage by weight: 45-65% of beta-nicotinamide mononucleotide, and the balance of roxburgh rose extract.
In one embodiment of the invention, the active ingredients of the composition comprising β -nicotinamide mononucleotide and rosa roxburghii tratt extract consist of the following components in percentage by weight: 50-60% of beta-nicotinamide mononucleotide, and the balance of rosa roxburghii tratt extract.
In a specific embodiment of the invention, the active ingredients of the composition comprising beta-nicotinamide mononucleotide and rosa roxburghii tratt extract consist of the following components in percentage by weight: beta-nicotinamide mononucleotide 50%, and roxburgh rose extract in balance.
In one embodiment of the present invention, the rosa roxburghii tratt extract of the present invention is an aqueous extract.
In one embodiment of the invention, the composition comprising beta-nicotinamide mononucleotide and rosa roxburghii tratt extract further comprises an auxiliary material acceptable for food.
In one embodiment of the present invention, the composition comprising β -nicotinamide mononucleotide and rosa roxburghii tratt extract is a granule, a tablet, a capsule, a pill, a paste, a beverage or a biscuit.
The invention also provides application of the composition containing the beta-nicotinamide mononucleotide and the roxburgh rose extract in preparing health care products or medicines for improving intestinal flora disorder.
The composition containing the beta-nicotinamide mononucleotide and the rosa roxburghii tratt extract can improve the intestinal flora, increase the number of lactobacillus and bifidobacteria and help to improve the intestinal flora disorder.
The invention also provides application of the composition containing the beta-nicotinamide mononucleotide and the roxburgh rose extract in preparing health-care products or medicines for delaying senescence.
The composition containing the beta-nicotinamide mononucleotide and the rosa roxburghii tratt extract can prolong the life of nematodes and delay senescence.
Compared with the prior art, the invention has the following beneficial effects:
according to the invention, through compounding of the NMN and the roxburgh rose extract, the NMN and the roxburgh rose extract are synergistic, so that the intestinal flora is obviously improved, the service life of nematodes is prolonged, the intestinal flora disorder can be effectively improved, and the aging is delayed. In addition, the composition has low cost and is convenient to popularize.
Drawings
FIG. 1 is a graph of a colony composition analysis (mean value) in test example 2 of the present invention, wherein A is a relative abundance of intestinal flora at a phylum level; panel B is the relative abundance of intestinal flora at the genus level.
FIG. 2 is a graph showing the Alpha diversity analysis of the ileocecal flora of mice in test example 2 of the present invention.
FIG. 3 is a graph showing the diversity of Beta PCoA in ileocecal flora in mice in test example 2 of the present invention.
Detailed Description
The invention relates to a composition containing beta-nicotinamide mononucleotide and a roxburgh rose extract, which comprises the following active ingredients in percentage by weight: 45-65% of beta-nicotinamide mononucleotide, and the balance of roxburgh rose extract.
The invention achieves the purpose of mutual synergy through the specific proportion of the beta-nicotinamide mononucleotide and the rosa roxburghii tratt extract, thereby enhancing the capacity of the composition for improving intestinal flora and resisting aging while reducing the dosage of NMN.
In one embodiment of the invention, the active ingredient of the composition comprising β -nicotinamide mononucleotide and rosa roxburghii tratt extract consists of the following components in percentage by weight: beta-nicotinamide mononucleotide 50-60 wt%, and roxburgh rose extract for the rest.
In a specific embodiment of the invention, the active ingredients of the composition comprising β -nicotinamide mononucleotide and rosa roxburghii tratt extract consist of the following components in percentage by weight: beta-nicotinamide mononucleotide 50%, and roxburgh rose extract in balance.
The roxburgh rose extract is an aqueous extract. The fructus Rosae Normalis extract is rich in SOD, fructus Rosae Normalis polysaccharide, fructus Rosae Normalis polyphenol or vitamin C, etc., and can be commercially available fructus Rosae Normalis extract.
The composition comprises beta-nicotinamide mononucleotide and a roxburgh rose extract, and also comprises auxiliary materials acceptable for food.
Can be prepared into the dosage form commonly used in the field by adding auxiliary materials. In one embodiment of the present invention, the composition comprising β -nicotinamide mononucleotide and rosa roxburghii tratt extract is a granule, a tablet, a capsule, a pill, a paste, a beverage or a biscuit.
The composition of the present invention comprising β -nicotinamide mononucleotide and rosa roxburghii tratt extract can be prepared by a conventional method, and in one embodiment of the present invention, can be prepared by:
and uniformly mixing the beta-nicotinamide mononucleotide, the roxburgh rose extract and auxiliary materials to obtain the composition containing the beta-nicotinamide mononucleotide and the roxburgh rose extract.
The composition containing the beta-nicotinamide mononucleotide and the roxburgh rose extract can be applied to preparation of health-care products or medicines for improving intestinal flora disorder.
The composition containing the beta-nicotinamide mononucleotide and the roxburgh rose fruit extract can improve the intestinal flora, increase the number of lactobacillus and bifidobacterium and help to improve the intestinal flora disorder.
The composition containing the beta-nicotinamide mononucleotide and the roxburgh rose extract can be applied to preparation of health-care products or medicines for delaying senescence.
The composition containing the beta-nicotinamide mononucleotide and the rosa roxburghii tratt extract can prolong the life of nematodes and delay senescence.
The following examples are provided to further illustrate the embodiments of the present invention and are not intended to limit the scope of the present invention. The Rosa roxburghii extract in the examples was purchased from Sai' an Ruelin Biotech Co., ltd, and was prepared from beta-nicotinamide mononucleotide.
Example 1
The embodiment provides a composition, the total mass of which is 50g, wherein the mass fractions of the main components of the composition are as follows: weighing the two raw materials according to the proportion of 50 percent of beta-nicotinamide mononucleotide and 50 percent of roxburgh rose extract, and uniformly mixing.
Example 2
The embodiment provides a composition, the total mass of which is 50g, wherein the mass fractions of the main components of the composition are as follows: 60% of beta-nicotinamide mononucleotide and 40% of roxburgh rose extract, weighing the two raw materials according to the proportion, and uniformly mixing.
Comparative example 1
The comparative example provides a composition, the total mass of the composition being 50g, wherein the mass fractions of the main components of the composition are: weighing the two raw materials according to the proportion of 10 percent of beta-nicotinamide mononucleotide and 90 percent of roxburgh rose extract, and uniformly mixing.
Comparative example 2
The comparative example provides a composition, the total mass of which is 50g, wherein the mass fractions of the main components of the composition are: 20 percent of beta-nicotinamide mononucleotide and 80 percent of roxburgh rose extract are weighed according to the proportion and mixed evenly.
Comparative example 3
The comparative example provides a composition, the total mass of the composition being 50g, wherein the mass fractions of the main components of the composition are: 30 percent of beta-nicotinamide mononucleotide and 70 percent of roxburgh rose extract, weighing the two raw materials according to a proportion, and uniformly mixing.
Comparative example 4
The comparative example provides a composition, the total mass of which is 50g, wherein the mass fractions of the main components of the composition are: weighing the two raw materials according to the proportion of 40 percent of beta-nicotinamide mononucleotide and 60 percent of roxburgh rose extract, and uniformly mixing.
Comparative example 5
The comparative example provides a composition, the total mass of the composition being 50g, wherein the mass fractions of the main components of the composition are: 70 percent of beta-nicotinamide mononucleotide and 30 percent of roxburgh rose extract, weighing the two raw materials according to a proportion, and uniformly mixing.
Comparative example 6
The comparative example provides a composition, the total mass of the composition being 50g, wherein the mass fractions of the main components of the composition are: 80% of beta-nicotinamide mononucleotide and 20% of roxburgh rose extract, weighing the two raw materials according to the proportion, and uniformly mixing.
Comparative example 7
The comparative example provides a composition, the total mass of which is 50g, wherein the mass fractions of the main components of the composition are: 90 percent of beta-nicotinamide mononucleotide and 10 percent of roxburgh rose extract are weighed according to the proportion and mixed evenly.
Test example 1 Effect of the composition on intestinal flora of Human Flora (HFA) mouse model
(1) Construction of HFA mouse model
A healthy volunteer, female, 25 years old, was selected to be not taking any antibiotics within 3 months. Collecting fresh feces excreted by volunteers for the first time in the morning, weighing the feces under aseptic and anaerobic conditions, adding the feces into Wilkins-Chalgren anaerobic bacteria broth (feces: broth = 1g. 4-week-old KM mice were weighed 22. + -.3 g, and female and male half respectively. And (3) performing intragastric administration on each KM mouse by 0.3mL of the fecal suspension, culturing for 21 days, and performing field planting on human intestinal flora in the mouse to obtain an HFA mouse model. HFA mice are bred in SPF animal rooms, and are bred with sterile mouse-based feed and sterile water, and drinking water is freely taken during the experiment.
(2) Effect of the composition on the intestinal flora of the HFA model
HFA mice were randomly grouped into 10 mice each, a blank solvent control group, a beta-nicotinamide mononucleotide group, a Rosa roxburghii extract group and the composition groups of examples 1-2 and comparative examples 1-7 were set, the administration doses were all 100mg/kg, and the samples were usedDissolved in physiological saline, and each gavage is 0.3mL. During the experiment, the mice were subjected to regular intragastric administration every day, the blank solvent control group was intragastric administered with physiological saline of the same volume every day, and the mice were continuously intragastric administered for 21 days during the raising period, and were allowed to freely eat water. The weight change of each group of mice is recorded during the experiment period, after the mice are killed on the 22 th day, the cecum contents are collected aseptically and placed in an aseptic test tube, the cecum contents are weighed on an ultra-clean bench, and are mixed with aseptic normal saline according to 1:9 (g/V), and are shaken on a shaker for 15min, so as to obtain the intestinal content suspension. Taking 6 test tubes filled with 9mL of sterilized normal saline, and sequentially diluting the cecal contents until the dilution ratio is 10 -5 . Sample dilution according to Bifidobacterium (10) -3 、10 -4 、10 -5 ) Lactobacillus (10) -3 、10 -4 、10 -5 ) Enterobacter (10) -2 、10 -3 、10 -4 ) Enterococcus (10) -2 、10 -3 、10 -4 ) 0.2mL of samples of different dilutions were pipetted onto different selective media and plated for culture, 3 parallel plates per medium at each dilution. The culture conditions and identification methods of different intestinal flora are shown in table 1.
TABLE 1 culture conditions and identification method of intestinal flora
After the culture is finished, counting by a conventional flat plate viable count method, calculating the average colony number alpha of the same dilution of various colonies, respectively calculating the total number of the colonies of 3 dilution samples of various colonies according to a formula, and finally expressing the final result by the logarithmic value of the colony number in per gram of excrement. When counting, selecting the plate with 30-300 plate colonies.
Total number of colonies [ l g (CFU/g) ] = α × dilution factor/0.1
The weight change of the mice before and after the experiment and the number of bacteria in the intestinal tract of the mice are shown in Table 2.
Table 2 weight change of mice and number of bacteria in mouse intestinal tract before and after experiment (n = 10)
Note: p <0.05, P <0.01, P <0.001, compared to solvent control group
As can be seen from Table 2, the weight of the mice was increased at the end of the experiment as compared with the solvent control group. Compared with the solvent group, the body weight of mice in the NMN group and the composition group in the example 1 is obviously lower than that in the solvent group, which shows that the NMN and the compositions in the examples 1 and 2 have obvious weight-reducing effect, and the weight-reducing effect of the compositions in the examples 1 and 2 is better than that of the NMN. Compared with the solvent group, the NMN has no obvious influence on the intestinal flora of HFA mice when the concentration of the NMN is 100mg/kg, and the roxburgh rose extract can increase the number of lactobacillus and bifidobacterium and reduce the number of enterobacteria and enterococcus. When NMN is used in combination with the rosa roxburghii extract, there is a tendency for the numbers of lactobacilli and bifidobacteria in the intestine to increase first and then decrease, and for enterobacteria and enterococci in the intestine to decrease first and then increase, with increasing proportion of the rosa roxburghii extract, and in particular the compositions of examples 1 and 2, the differences in the increase in the numbers of lactobacilli and bifidobacteria are very significant compared to the solvent group. Therefore, after the NMN is combined with the roxburgh rose extract, the synergistic effect is achieved, and an unexpected improvement effect is achieved on the intestinal flora of the mouse in the HFA model.
Test example 2 reconstitution of antibiotic-induced intestinal flora disorders with the composition
According to test example 1, the composition of example 1 has a significant improvement effect on the intestinal flora of HFA model mice, and this test example will further examine the reconstitution effect of the composition of example 1 on antibiotic-induced intestinal flora disorders.
(1) Establishment of mouse intestinal flora imbalance model
The experiment was started after 4-week-old KM mice, half male and half female, weighing 22 + -3 g, were acclimatized for one week. 5 female and 5 male mice were randomly left as a normal control group (Nor group), and the rest were gavaged with lincomycin hydrochloride solution at 12mL/kg 2 times a day for 7 consecutive days, and the normal control group was given an equal volume of physiological saline by gavage. After 7d, 5 female mice and 5 male mice were selected from the mice with diarrhea, sacrificed and used as a model group (Mod group), feces of the mice returning to the cecum part were collected under aseptic conditions, and the feces properties were observed for 16S rRNA detection.
(2) Mouse grouping and drug treatment
Mice with diarrhea were randomly grouped into 10 mice each, a natural recovery group (Con), a beta-nicotinamide mononucleotide group (NMN, 100 mg/kg), a Rosa roxburghii extract group (CL, 100 mg/kg) and the composition of example 1, a high dose (200 mg/kg) group [ NMN + CL (H) ] and a low dose group (100 mg/kg) of [ NMN + CL (L) ], and the composition was dissolved in physiological saline 0.3mL per gavage. During the experiment, the mice are subjected to regular intragastric administration every day, the natural recovery group is subjected to intragastric administration of normal saline with the same volume every day and is continuously subjected to intragastric administration for 7 days, and the mice freely eat drinking water during the feeding period. The change in body weight of each group of mice was recorded during the experiment, and after the mice were sacrificed on day 8, feces were aseptically collected from the cecal area of each group and observed for their behavior for 16S rRNA detection.
(3) High-throughput sequencing of intestinal microorganisms and flora analysis thereof
Total genomic DNA extraction was performed on mouse fecal samples using a specific DNA extraction kit, and after DNA integrity and concentration were tested, the 1696 rDNA V4 region of the sample was amplified with the amplification primer sequences 515F (5 '-GTGYCAGCMGCCGCGGTAA-3') and 806R (5 '-GGACTACHVGGGT WTCTAAT-3'). And (3) carrying out electrophoresis detection on the target fragment after amplification, taking a target strip from a sample which is qualified for detection, recovering, and constructing a library for high-throughput sequencing. The sequencing result is spliced and filtered to obtain a high-quality target sequence, and bioinformatics analysis including community composition analysis, alpha diversity analysis, beta diversity analysis and the like is performed, and the result is shown in figures 1 to 3.
As can be seen from A in FIG. 1, at the phylum level, the normal group returned to the cecum with Bacteroides, firmicutes and Proteobacteria as the main phyla. After lincomycin is irrigated, the abundance of bacteroidetes in cecum of the mice is reduced sharply, and the abundance of proteobacteria and firmicutes is greatly improved. After NMN or Rosa roxburghii extract is drenched, the abundance of Bacteroides, firmicutes and Proteobacteria is restored. When the composition of example 1 was administered, both the low dose group (100 mg/kg) [ NMN + CL (L) and the high dose group (200 mg/kg) [ NMN + CL (H) significantly restored the abundance of bacteroidetes, firmicutes and proteobacteria, increased bacteroidetes abundance and decreased proteobacteria and firmicutes abundance. The composition of the NMN and the roxburgh rose extract effectively increases the content of beneficial bacteria in intestinal tracts of mice with dysbacteriosis, inhibits harmful bacteria and enables the composition of the intestinal flora to approach a normal level.
It can be seen from B of fig. 1 that, after lincomycin treatment, the abundance of bacteroides, parabacteroides, eckmann, enterobacter and pilospira in the mouse ileocecum was significantly decreased and the abundance of staphylococcus and pseudomonas was greatly increased at the genus level. After drenching with NMN and Rosa roxburghii extract, the abundance of Bacteroides and Acermann in ileocecal part was partially increased. When the composition of example 1 was administered, the low dose group (100 mg/kg) [ NMN + CL (L) and the high dose group (200 mg/kg) [ NMN + CL (H) both significantly increased the abundance of beneficial bacteria bacteroides, parabacteroides, eckermann, lachnospirillum, etc., and significantly suppressed the abundance of harmful bacteria such as pseudomonas, staphylococcus, etc. The NMN and roxburgh rose composition can effectively promote beneficial bacteria in intestinal tracts of mice and inhibit harmful bacteria in the intestinal tracts.
FIG. 2 shows the results of Alpha diversity analysis of mouse ileocecal flora. As can be seen from FIG. 2, after lincomycin is infused, the abundance and diversity of intestinal flora are greatly lower than those of normal mice. After NMN and the roxburgh rose extract are given, the abundance and diversity of the flora are improved compared with those of a model group. Both the low dose group (100 mg/kg) [ NMN + CL (L) and the high dose group (200 mg/kg) [ NMN + CL (H) significantly increased the abundance and diversity of the flora when the composition of example 1 was administered.
FIG. 3 is Beta diversity analysis of mouse ileocecal flora, and it can be seen from FIG. 3 that the flora structure is significantly different from that of the normal group and the diversity of the flora is reduced after lincomycin treatment. After NMN and the rosa roxburghii tratt extract are given, the diversity of the flora is improved. Both the low dose group (100 mg/kg) [ NMN + CL (L) and the high dose group (200 mg/kg) [ NMN + CL (H) resulted in a significant increase in microflora diversity when the composition of example 1 was administered.
In conclusion, the combination of NMN and rosa roxburghii has a restorative effect on the intestinal flora of antibiotic-induced dysbacteriosis mice.
Test example 3 composition anti-aging Activity test
(1) Experimental Material
Experimental nematode strains: wild-type nematode strain c.elegans Bristol N2
Experimental strains: uracil-deficient Escherichia coli (OP 50) which cannot synthesize uracil by itself and requires the uptake of uracil for self-growth from a solid medium.
The experimental liquid medicine and the preparation method are as follows: NMN, the Rosa roxburghii extract and the compositions of example 1, example 2 and comparative examples 1-7 were dissolved in physiological saline and sterilized by filtration through a 0.22 μm aqueous microporous membrane in a clean bench. Subpackaging into 1mL sterile EP tubes, sealing with sealing film, and placing in refrigerator for use. When in use, the liquid medicine is opened in a clean bench, shaken up and diluted with culture medium to the concentration of 100, 250 and 500mg/mL.
(2) Caenorhabditis elegans experimental method
The experiment is divided into an experimental group and a control group, synchronized caenorhabditis elegans is cultured to a young adult stage in a biochemical incubator, the caenorhabditis elegans which has good growth state and uniform polypide size is picked up to an NGM 6 pore plate coated with OP50 bacteria under a stereoscope, each pore is about 150 caenorhabditis elegans, the polypide size is kept consistent as much as possible, and the number of the experimental group and the control group is kept consistent. The experimental group lays a layer of liquid medicine on an NGM plate coated with OP50 bacteria, the control group lays a culture medium, the first day of the life days of the caenorhabditis elegans is recorded, the caenorhabditis elegans needs to be observed and transferred to a new clean NGM 6 pore plate every day in the first seven days, the living state of the caenorhabditis elegans is ensured to be good, food is sufficient, and the caenorhabditis elegans is not polluted by other bacteria, the caenorhabditis elegans can be transferred every other day after the seventh day, because the caenorhabditis elegans almost do not have reproductive capacity any more, the growth condition of the caenorhabditis elegans needs to be observed every day and the number of the caenorhabditis elegans died every day, including normal death and abnormal death, and data are sorted. The method for judging the death of caenorhabditis elegans comprises the following steps: 1. the body of C.elegans was gently touched with platinum wire to observe whether or not the C.elegans responded. 2. The observation was made under a microscope whether the caenorhabditis elegans had a twitch in the pharynx. The results are shown in Table 3.
TABLE 3 Effect of compositions on caenorhabditis elegans longevity
Note: p <0.05, P <0.01, P <0.001, compared to solvent control group
As can be seen from table 3, both NMN and the rosa roxburghii tratt extract can prolong the lifespan of nematodes, but when NMN and rosa roxburghii tratt extract are mixed in a certain ratio, the activity of prolonging the lifespan of nematodes is significantly higher than that of either NMN or rosa roxburghii tratt extract when used alone, even though the dosages of NMN and rosa roxburghii tratt extract are reduced by half.
In conclusion, after the NMN is combined with the roxburgh rose extract, the synergy is realized, the abundance of beneficial bacteria can be improved, the abundance of harmful bacteria can be reduced, and the diversity index and the abundance of intestinal microorganisms can be obviously improved. Has unexpected effects on improving intestinal flora and delaying senility.
Claims (8)
1. Composition comprising beta-nicotinamide mononucleotide and rosa roxburghii tratt extract, characterized in that the active ingredients thereof consist of the following components in percentage by weight: 45-65% of beta-nicotinamide mononucleotide, and the balance of roxburgh rose extract.
2. The composition of claim 1, wherein the active ingredients comprise the following components in weight percent: beta-nicotinamide mononucleotide 50-60 wt%, and roxburgh rose extract for the rest.
3. The composition of claim 1, wherein the active ingredients comprise the following components in weight percent: beta-nicotinamide mononucleotide 50%, and roxburgh rose extract in balance.
4. The composition comprising β -nicotinamide mononucleotide and Rosa roxburghii extract according to any one of claims 1-3, characterized in that: the Rosa roxburghii extract is an aqueous extract.
5. A composition comprising β -nicotinamide mononucleotide and a rosa roxburghii tratt extract according to any one of claims 1 to 3, characterized in that: also comprises auxiliary materials acceptable for food.
6. The composition comprising β -nicotinamide mononucleotide and Rosa roxburghii extract according to any one of claims 1-3, characterized in that: the composition containing the beta-nicotinamide mononucleotide and the roxburgh rose extract is granules, tablets, capsules, pills, paste, beverage or biscuits.
7. Use of a composition comprising β -nicotinamide mononucleotide and Rosa roxburghii extract according to any one of claims 1-6 for the preparation of a health product or a pharmaceutical product for ameliorating a disturbed intestinal flora.
8. Use of a composition comprising β -nicotinamide mononucleotide and Rosa roxburghii extract according to any one of claims 1-6 for the preparation of a health product or a pharmaceutical product for delaying aging.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110831357.4A CN115671178A (en) | 2021-07-22 | 2021-07-22 | Composition comprising beta-nicotinamide mononucleotide and rosa roxburghii tratt extract and application thereof |
| PCT/CN2021/111762 WO2023000408A1 (en) | 2021-07-22 | 2021-08-10 | COMPOSITION COMPRISING β-NICOTINAMIDE MONONUCLEOTIDE AND ROXBURGH ROSE EXTRACT, AND APPLICATION THEREOF |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110831357.4A CN115671178A (en) | 2021-07-22 | 2021-07-22 | Composition comprising beta-nicotinamide mononucleotide and rosa roxburghii tratt extract and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115671178A true CN115671178A (en) | 2023-02-03 |
Family
ID=84979687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110831357.4A Pending CN115671178A (en) | 2021-07-22 | 2021-07-22 | Composition comprising beta-nicotinamide mononucleotide and rosa roxburghii tratt extract and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN115671178A (en) |
| WO (1) | WO2023000408A1 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102266043A (en) * | 2010-06-04 | 2011-12-07 | 钱立奎 | Novel production technology of nutrient health Rosa roxburghii solid beverage |
| CN104814974A (en) * | 2015-03-16 | 2015-08-05 | 邦泰生物工程(深圳)有限公司 | Application of nicotinamide mononucleotide in preparation of anti-aging drugs or health care products |
| CN109674808A (en) * | 2019-01-30 | 2019-04-26 | 四川大学 | β-nicotinamide mononucleotide or its precursor are preparing the purposes delayed in lung senescence drug |
| CN110974843A (en) * | 2019-12-23 | 2020-04-10 | 美益添生物医药(武汉)有限公司 | Composition and application thereof in balancing NO producing bacteria ratio in intestinal flora |
| CN112273649A (en) * | 2020-11-03 | 2021-01-29 | 深圳市新靶向生物科技有限公司 | Antioxidant and anti-aging composition, preparation method and application |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016188092A1 (en) * | 2015-12-11 | 2016-12-01 | 邦泰生物工程(深圳)有限公司 | Use of nicotinamide mononucleotide in preparing health care products for prevention and treatment of arteriosclerosis and cardiovascular and cerebrovascular diseases, and health care product thereof |
| CN106617026A (en) * | 2016-10-24 | 2017-05-10 | 烟台燕园科玛健康产业有限公司 | Aging preventing food composition |
| CN110338412A (en) * | 2019-07-16 | 2019-10-18 | 深圳市弘创农业科技有限公司 | The composition and its preparation of niacinamide-containing mononucleotide and ice plant and application |
| CN111557949B (en) * | 2020-05-28 | 2022-08-26 | 深圳爱生生命科技有限公司 | Medicine or health product containing hydrogen-rich water and/or NMN and preparation method thereof |
| DE202020105398U1 (en) * | 2020-09-21 | 2020-11-11 | BIODOMO Vertriebsgesellschaft für biologische Produkte mbH | Food supplement, capsule and packaging unit |
| US20210077515A1 (en) * | 2020-10-12 | 2021-03-18 | Hangzhou Huadong Medicine Comprehensive Health Development Co., Ltd. | Compositions containing beta-nicotinamide mononucleotide and cordyceps sinensis and use thereof |
| CN112089775A (en) * | 2020-10-30 | 2020-12-18 | 成都及禾生物科技有限公司 | NMN beneficial bacterium health composition and preparation method and application thereof |
-
2021
- 2021-07-22 CN CN202110831357.4A patent/CN115671178A/en active Pending
- 2021-08-10 WO PCT/CN2021/111762 patent/WO2023000408A1/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102266043A (en) * | 2010-06-04 | 2011-12-07 | 钱立奎 | Novel production technology of nutrient health Rosa roxburghii solid beverage |
| CN104814974A (en) * | 2015-03-16 | 2015-08-05 | 邦泰生物工程(深圳)有限公司 | Application of nicotinamide mononucleotide in preparation of anti-aging drugs or health care products |
| CN109674808A (en) * | 2019-01-30 | 2019-04-26 | 四川大学 | β-nicotinamide mononucleotide or its precursor are preparing the purposes delayed in lung senescence drug |
| CN110974843A (en) * | 2019-12-23 | 2020-04-10 | 美益添生物医药(武汉)有限公司 | Composition and application thereof in balancing NO producing bacteria ratio in intestinal flora |
| CN112273649A (en) * | 2020-11-03 | 2021-01-29 | 深圳市新靶向生物科技有限公司 | Antioxidant and anti-aging composition, preparation method and application |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023000408A1 (en) | 2023-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110964655B (en) | Bifidobacterium lactis BL-99 and application thereof | |
| Westfall et al. | A novel polyphenolic prebiotic and probiotic formulation have synergistic effects on the gut microbiota influencing Drosophila melanogaster physiology | |
| CN110964653B (en) | Lactobacillus paracasei ET-22 capable of adjusting intestinal flora balance | |
| CN116286551B (en) | Application of bifidobacterium longum subspecies infantis in regulating in-vivo fat metabolism, shaping, reducing fat and improving obesity | |
| KR20180106987A (en) | Lactobacillus plantarum tci378 and its uses in losing fat and improving gastrointestinal functions | |
| CN101277712A (en) | The composition comprising extract of cinnamomum cassia bark for improving normal flora and enhancing immune response | |
| CN114574406B (en) | Lactobacillus rhamnosus strain WKA55, and application and product thereof in preparation of product for preventing and treating alcoholic liver injury | |
| CN102618452B (en) | Preparation method, composition and application of lactobacillus salivarius and its metabolites | |
| CN114480193A (en) | Application of bacillus coagulans in preparation of food or medicine for improving organism function reduction caused by hyperglycemia and hyperlipidemia | |
| KR20130084891A (en) | Fermentation product of scutellaria baicalensis and antibacterial and immune enhancing composition comprising the same | |
| JP6793380B2 (en) | Evaluation method, screening method and manufacturing method of substances that suppress the rise in blood glucose level due to sucrose intake | |
| JP6301024B2 (en) | Felicaribacterium spp. | |
| US11478525B2 (en) | Method for promoting growth of Akkermansia muciniphila using musa ferments | |
| CN116121154B (en) | Leuconostoc lactis and application thereof | |
| CN115671178A (en) | Composition comprising beta-nicotinamide mononucleotide and rosa roxburghii tratt extract and application thereof | |
| Yücer et al. | The antiproliferative and antimicrobial effects of cultivated Anabaena circinalis Rabenhorts ex Bornet and Flahault and Nostoc entophytum Bornet and Flahault | |
| CN110123824B (en) | Ilicis Pubescentis saponin A1New use of | |
| CN114164157A (en) | Lactobacillus salivarius strain ZK-88 for inhibiting inflammation, relieving swelling and aching of gum, and improving oral flora balance | |
| CN113967243A (en) | Fermented traditional Chinese medicine preparation for preventing and treating poultry diarrhea and preparation method thereof | |
| CN113892642B (en) | Probiotic composition for relaxing bowel | |
| TWI810645B (en) | Lactobacillus composition and use thereof for improving anxiety caused by antibiotics | |
| CN108524749A (en) | A kind of Chinese medicine composition and application for improving intestinal flora distribution | |
| CN114164158B (en) | Bifidobacterium strain ZK-77 for inhibiting pathogenic bacteria, relieving inflammation, and balancing flora | |
| CN116875481A (en) | Lactobacillus plantarum and application thereof in preparation of irritable bowel syndrome drugs | |
| CN115960784A (en) | Lactobacillus plantarum ZJUF SYS1 and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |